The Journal of Neuroscience, October 11, 2006, 26(41):10614-10619; doi:10.1523/JNEUROSCI.3582-06.2006
Previous Article
Brief Communications
An Inhibitor of Serine Proteases, Neuroserpin, Acts as a Neuroprotective Agent in a Mouse Model of Neurodegenerative Disease
Yannick Simonin,1
Yves Charron,2
Peter Sonderegger,3
Jean-Dominique Vassalli,2 and
Ann C. Kato1
1Departments of Basic Neurosciences and 2Genetic Medicine and Development, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland, and 3Institute of Biochemistry, University of Zurich, CH-8057 Zurich, Switzerland
Correspondence should be addressed to Ann C. Kato, Department of Basic Neuroscience, Centre Médical Universitaire, 1 rue Michel Servet, 1211 Geneva 4, Switzerland. Email: ann.kato{at}medecine.unige.ch
Various studies suggest that proteolytic activity may be involved in a number of neurodegenerative disorders, including stroke and seizure. In this report, we examined the role of tryptic serine proteases, plasminogen activators (PAs), in the evolution of a neurodegenerative disease. Transgenic mice overexpressing an axonally secreted inhibitor of serine proteases (neuroserpin) were crossed with mice characterized by a "dying-back" motor neuron disease [progressive motor neuronopathy (pmn/pmn)]. Compared with pmn/pmn mice that showed an increase in PA activity, double mutant mice had decreased PA activity in sciatic nerves and spinal cord; their lifespan was increased by 50%, their motor behavior was stabilized, and histological analysis revealed increased numbers of myelinated axons and rescue of motoneuron number and size. This is the first report showing that a class of serine proteases (PAs) may be involved in the pathogenesis of a motor neuron disease and more specifically in axonal degeneration. Inhibiting serine proteases could offer a new strategy for delaying these disorders.
Key words: motoneurons; axon; spinal cord; plasminogen activator; neuroserpin; pmn mice
Received July 4, 2006;
accepted Sept. 7, 2006.
Correspondence should be addressed to Ann C. Kato, Department of Basic Neuroscience, Centre Médical Universitaire, 1 rue Michel Servet, 1211 Geneva 4, Switzerland. Email: ann.kato{at}medecine.unige.ch
Related articles in J. Neurosci.:
- This Week in The Journal
J. Neurosci. 2006 26: i.
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
E. E. Benarroch
Tissue plasminogen activator: Beyond thrombolysis
Neurology,
August 21, 2007;
69(8):
799 - 802.
[Full Text]
[PDF]
|
 |
|